Francois Michelon - ENDRA Life Chairman of the Board, CEO
| NDRA Stock | USD 4.30 0.27 6.70% |
Chairman
Mr. Francois Michelon serves as Chairman of the Board, Chief Executive Officer of the Company. He joined ENDRA as Chief Executive Officer and Chairman of the Board of Directors in 2015. He has 18 years of healthcare technology experience in general management, operations, strategy and marketing across the diagnostic imaging, surgical instrument and dental sectors. From 2012 to 2014, Mr. Michelon served as Vice President of Global Marketing for the 3i division of Biomet, Inc., a provider of oral reconstruction technologies, where he was responsible for the upstream and downstream development of the divisions global portfolio. From 2004 to 2011, Mr. Michelon served as Group Director of Global Services and Visualization for Smith Nephew plcs Advanced Surgical Devices division, where he led PLs in the B2B service and capital equipment sectors. From 1997 to 2004, Mr. Michelon worked at GE Healthcare in a variety of global upstream and downstream marketing roles since 2015.
| Age | 58 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 734 335 0468 |
| Web | https://endrainc.com |
Francois Michelon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Francois Michelon against ENDRA Life stock is an integral part of due diligence when investing in ENDRA Life. Francois Michelon insider activity provides valuable insight into whether ENDRA Life is net buyers or sellers over its current business cycle. Note, ENDRA Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell ENDRA Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Francois Michelon over three weeks ago Disposition of tradable shares by Francois Michelon of ENDRA Life at 0.87 subject to Rule 16b-3 | ||
Francois Michelon over three months ago Acquisition by Francois Michelon of 713132 shares of ENDRA Life subject to Rule 16b-3 | ||
Francois Michelon over a year ago Acquisition by Francois Michelon of 69531 shares of ENDRA Life subject to Rule 16b-3 |
ENDRA Life Management Efficiency
The company has return on total asset (ROA) of (0.624) % which means that it has lost $0.624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4945) %, meaning that it created substantial loss on money invested by shareholders. ENDRA Life's management efficiency ratios could be used to measure how well ENDRA Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Erez Raphael | DarioHealth Corp | 52 | |
Management Performance
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.62 |
ENDRA Life Sciences Leadership Team
Elected by the shareholders, the ENDRA Life's board of directors comprises two types of representatives: ENDRA Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ENDRA. The board's role is to monitor ENDRA Life's management team and ensure that shareholders' interests are well served. ENDRA Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ENDRA Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Thornton, Chief Officer | ||
| Renaud Maloberti, Chief Commercial Officer | ||
| Ziad Rouag, Head Affairs | ||
| Alexander Tokman, Acting Chairman | ||
| Jonathan Behr, CoFounder | ||
| Francois Michelon, Chairman of the Board, CEO | ||
| Richard Jacroux, Chief Officer | ||
| Irina Pestrikova, Senior Secretary | ||
| Steve Freeman, Human Leader |
ENDRA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ENDRA Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | (2.22 M) | ||||
| Shares Outstanding | 536.91 K | ||||
| Shares Owned By Insiders | 0.14 % | ||||
| Shares Owned By Institutions | 0.02 % | ||||
| Number Of Shares Shorted | 31.2 K | ||||
| Price To Earning | (0.93) X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (9.78 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in ENDRA Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ENDRA Life. If investors know ENDRA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ENDRA Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ENDRA Life Sciences is measured differently than its book value, which is the value of ENDRA that is recorded on the company's balance sheet. Investors also form their own opinion of ENDRA Life's value that differs from its market value or its book value, called intrinsic value, which is ENDRA Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ENDRA Life's market value can be influenced by many factors that don't directly affect ENDRA Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ENDRA Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if ENDRA Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ENDRA Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.